|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lerouge D, Riviere A, Dansin E, Chouaid C,
Dujon C, Schott R, Lavole A, Le Pennec V, Fabre E, Crequit J, et
al: A phase II study of cisplatin with intravenous and oral
vinorelbine as induction chemotherapy followed by concomitant
chemoradiotherapy with oral vinorelbine and cisplatin for locally
advanced non-small cell lung cancer. BMC Cancer. 14:2312014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jakopovic M, Thomas A and Lopez-Chavez A:
From platinum compounds to targeted therapies in advanced thoracic
malignancies. Anticancer Res. 34:477–482. 2014.PubMed/NCBI
|
|
4
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I: Recent cancer survival
in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet
Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chi YC, Lin SP and Hou YC: A new herb-drug
interaction of Polygonum cuspidatum, a resveratrol-rich
nutraceutical, with carbamazepine in rats. Toxicol Appl Pharmacol.
263:315–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Das S and Das DK: Resveratrol: a
therapeutic promise for cardiovascular diseases. Recent Pat
Cardiovasc Drug Discov. 2:133–138. 2007. View Article : Google Scholar
|
|
7
|
Demoulin B, Hermant M, Castrogiovanni C,
Staudt C and Dumont P: Resveratrol induces DNA damage in colon
cancer cells by poisoning topoisomerase II and activates the ATM
kinase to trigger p53-dependent apoptosis. Toxicol In Vitro.
29:1156–1165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Narayanan BA, Narayanan NK, Re GG and
Nixon DW: Differential expression of genes induced by resveratrol
in LNCaP cells: P53-mediated molecular targets. Int J Cancer.
104:204–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stewart JR, Ward NE, Ioannides CG and
O'Brian CA: Resveratrol preferentially inhibits protein kinase
C-catalyzed phosphorylation of a cofactor-independent,
arginine-rich protein substrate by a novel mechanism. Biochemistry.
38:13244–13251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tinhofer I, Bernhard D, Senfter M, Anether
G, Loeffler M, Kroemer G, Kofler R, Csordas A and Greil R:
Resveratrol, a tumor-suppressive compound from grapes, induces
apoptosis via a novel mitochondrial pathway controlled by Bcl-2.
FASEB J. 15:1613–1615. 2001.PubMed/NCBI
|
|
11
|
Mahyar-Roemer M, Kohler H and Roemer K:
Role of Bax in resveratrol-induced apoptosis of colorectal
carcinoma cells. BMC Cancer. 2:272002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fontecave M, Lepoivre M, Elleingand E,
Gerez C and Guittet O: Resveratrol, a remarkable inhibitor of
ribonucleotide reductase. FEBS Lett. 421:277–279. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ly JD, Grubb DR and Lawen A: The
mitochondrial membrane potential (deltapsi(m)) in apoptosis; an
update. Apoptosis. 8:115–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Porter AG and Janicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wightman EL, Reay JL, Haskell CF,
Williamson G, Dew TP and Kennedy DO: Effects of resveratrol alone
or in combination with piperine on cerebral blood flow parameters
and cognitive performance in human subjects: a randomised,
double-blind, placebo-controlled, cross-over investigation. Br J
Nutr. 112:203–213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kennedy DO, Wightman EL, Reay JL, Lietz G,
Okello EJ, Wilde A and Haskell CF: Effects of resveratrol on
cerebral blood flow variables and cognitive performance in humans:
a double-blind, placebo-controlled, crossover investigation. Am J
Clin Nutr. 91:1590–1597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aires V, Limagne E, Cotte AK, Latruffe N,
Ghiringhelli F and Delmas D: Resveratrol metabolites inhibit human
metastatic colon cancer cells progression and synergize with
chemo-therapeutic drugs to induce cell death. Mol Nutr Food Res.
57:1170–1181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mikstacka R and Ignatowicz E:
Chemopreventive and chemotherapeutic effect of trans-resveratrol
and its analogues in cancer. Pol Merkur Lekarski. 168:496–500.
2010.(In Polish).
|
|
19
|
Frampton GA, Lazcano EA, Li H, Mohamad A
and DeMorrow S: Resveratrol enhances the sensitivity of
cholangiocarcinoma to chemotherapeutic agents. Lab Invest.
90:1325–1338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hamada M, Sumida M, Okuda H, Watanabe T,
Nojima M and Kuby SA: Adenosine
triphosphate-adenosine-5′-monophosphate phosphotransferase from
normal human liver mitochondria. Isolation, chemical properties,
and immunochemical comparison with Duchenne dystrophic serum
aberrant adenylate kinase. J Biol Chem. 257:13120–13128.
1982.PubMed/NCBI
|
|
21
|
Lei T, Guo N, Tan MH and Li YF: Effect of
mouse oocyte vitrification on mitochondrial membrane potential and
distribution. J Huazhong Univ Sci Technolog Med Sci. 34:99–102.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diaz G, Setzu MD, Zucca A, Isola R, Diana
A, Murru R, Sogos V and Gremo F: Subcellular heterogeneity of
mitochondrial membrane potential: relationship with organelle
distribution and intercellular contacts in normal, hypoxic and
apoptotic cells. J Cell Sci. 112:1077–1084. 1999.PubMed/NCBI
|
|
23
|
Kosekova G, Mitovska M, Minkov I, Dancheva
K and Atanasov B: Effect of di-substituted cytochrome C pyridoxal
phosphate on oxidative phosphorylation in cytochrome C-deficient
liver mitochondria. Eksp Med Morfol. 20:12–17. 1981.(In
Bulgarian).
|
|
24
|
Wilson DF and Vinogradov SA: Mitochondrial
cytochrome c oxidase: mechanism of action and role in regulating
oxidative phosphorylation. J Appl Physiol. 117:1431–1439. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gleichmann M, Beinroth S, Reed JC,
Krajewski S, Schulz JB, Wullner U, Klockgether T and Weller M:
Potassium deprivation-induced apoptosis of cerebellar granule
neurons: cytochrome c release in the absence of altered expression
of Bcl-2 family proteins. Cell Physiol Biochem. 8:194–201. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karabay AZ, Aktan F, Sunguroglu A and
Buyukbingol Z: Methylsulfonylmethane modulates apoptosis of
LPS/IFN-gamma-activated RAW 264.7 macrophage-like cells by
targeting p53, Bax, Bcl-2, and PARP proteins. Immunopharmacol
Immunotoxicol. 36:379–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rong Y and Distelhorst CW: Bcl-2 protein
family members: versatile regulators of calcium signaling in cell
survival and apoptosis. Annu Rev Physiol. 70:73–91. 2008.
View Article : Google Scholar
|
|
28
|
Anvekar RA, Asciolla JJ, Missert DJ and
Chipuk JE: Born to be alive: a role for the BCL-2 family in
melanoma tumor cell survival, apoptosis, and treatment. Front
Oncol. 1:342011. View Article : Google Scholar
|
|
29
|
Yan W, Suominen J, Samson M, Jegou B and
Toppari J: Involvement of Bcl-2 family proteins in germ cell
apoptosis during testicular development in the rat and pro-survival
effect of stem cell factor on germ cells in vitro. Mol Cell
Endocrinol. 165:115–129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fletcher JI, Meusburger S, Hawkins CJ,
Riglar DT, Lee EF, Fairlie WD, Huang DC and Adams JM: Apoptosis is
triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc
Natl Acad Sci USA. 105:18081–18087. 2008. View Article : Google Scholar : PubMed/NCBI
|
